More deals ahead for Bristol Myers? CEO Giovanni Caforio touts 'size agnostic' BD strategy - Endpoints News
7/27/2022 12:00:00 AM2 years 9 months ago
by Nicole DeFeudis
by Nicole DeFeudis
Despite generics eating away at one of Bristol Myers Squibb’s highest sellers last year, Revlimid, CEO Giovanni Caforio maintained on Wednesday’s Q2 call that the company’s “foundation is strong” — and that he has all the tools necessary to keep building, inc…
Despite generics eating away at one of Bristol Myers Squibb’s highest sellers last year, Revlimid, CEO Giovanni Caforio maintained on Wednesday’s Q2 call that the company’s “foundation is strong” — a… [+672 chars]
full article...